Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eli Lilly and Company

https://www.lilly.com/

Latest From Eli Lilly and Company

Seven Potential Blockbuster Approvals To Look Out For In 2023

After highlighting oncology drugs pegged to make a splash next year with the help of Biomedtracker, Scrip takes a look at seven potential blockbusters across a range of therapeutic areas including neurology, dermatology and blood disorders slated for approval next year.

Approvals Companies

Keeping Track: US FDA Clears Santen’s Omlonti, Fennec’s Pedmark; Lilly’s Retevmo Adds Tumor-Agnostic Claim

The latest drug approval news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Approvals

Biogen/Eisai’s Lecanemab Suggests A New Model For Accelerated Approval In The US

Why not wait for the confirmatory trial to read out before approval, at least in the context of an especially uncertain or controversial surrogate marker?

Review Pathway Approvals

Medicare Part B Premium Reduction In 2023 Has Reserves Built In If Lecanemab Launches

But premiums in future years made need to keep pace with accelerating Medicare spending on Alzheimer’s drugs.

Reimbursement Medicare
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Alnara Pharmaceuticals, Inc.
    • ARMO BioSciences, Inc.
    • Applied Molecular Evolution
    • Avid Radiopharmaceuticals, Inc.
    • Bowfin Acquisition Corporation
    • Class AP
    • CoLucid Pharmaceuticals, Inc.
    • Dermira Inc.
    • Disarm Therapeutics, Inc.
    • Hypnion
    • ICOS Corporation
    • ImClone Systems
    • Loxo Oncology, Inc. (LOXO)
    • Protomer Technologies
    • SGX Pharmaceuticals (Structural GenomiX)
    • Valocor Therapeutics, Inc.
UsernamePublicRestriction

Register